학술논문

발행년
-
(예 : 2010-2015)
'학술논문' 에서 검색결과 136건 | 목록 1~10
Kroenke MA; Clinical Immunology, Amgen, Thousand Oaks, CA, United States.; Manning MS; Translational Safety & Bioanalytical Sciences, Amgen, Thousand Oaks, CA, United States.; Zuch de Zafra CL; Translational Safety & Bioanalytical Sciences, Amgen, South San Francisco, CA, United States.; Zhang X; Clinical Pharmacology, Modeling, and Simulation, Amgen, South San Francisco, CA, United States.; Cook KD; Pharmacokinetics and Drug Metabolism, Amgen, South San Francisco, CA, United States.; Archer M; Global Safety, Amgen, Thousand Oaks, CA, United States.; Lolkema MP; Early Development, Amgen, Thousand Oaks, CA, United States.; Wang J; Translational Safety & Bioanalytical Sciences, Amgen, Thousand Oaks, CA, United States.; Hoofring S; Translational Safety & Bioanalytical Sciences, Amgen, Thousand Oaks, CA, United States.; Saini G; Translational Safety & Bioanalytical Sciences, Amgen, Thousand Oaks, CA, United States.; Aeffner F; Translational Safety & Bioanalytical Sciences, Amgen, South San Francisco, CA, United States.; Ahern E; Medical Oncology, Monash Health, Clayton, VIC, Australia.; Cabanas EG; Research Unit, Hospital Universitario Vall d'Hebron, Barcelona, Spain.; Govindan R; Division of Hematology and Oncology, Washington University Medical School, St. Louis, MO, United States.; Hui M; Chris O'Brien Lifehouse, Camperdown, NSW, Australia.; Gupta S; Translational Safety & Bioanalytical Sciences, Amgen, Thousand Oaks, CA, United States.; Mytych DT; Clinical Immunology, Amgen, Thousand Oaks, CA, United States.
Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101560960 Publication Model: eCollection Cited Medium: Internet ISSN: 1664-3224 (Electronic) Linking ISSN: 16643224 NLM ISO Abbreviation: Front Immunol Subsets: PubMed not MEDLINE; MEDLINE
Academic Journal
Dorff T; Department of Medical Oncology and Therapeutics Research, City of Hope, Duarte, California.; Horvath LG; Department of Medical Oncology, Chris O'Brien Lifehouse, Camperdown, Australia.; Autio K; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.; Bernard-Tessier A; Department of Cancer Medicine, Institut Gustave Roussy, University of Paris Saclay, Villejuif, France.; Rettig MB; Departments of Medicine and Urology, University of California, Los Angeles, California.; Department of Medicine, VA Greater Los Angeles, Los Angeles, California.; Machiels JP; Department of Medical Oncology, Cliniques Universitaires Saint-Luc, Brussels, Belgium.; Bilen MA; Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, Georgia.; Lolkema MP; Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands.; Amgen Inc., Thousand Oaks, California.; Adra N; Department of Medicine, Indiana University School of Medicine, Indianapolis, Indiana.; Rottey S; Department of Medical Oncology. Drug Research Unit, Ghent University, Ghent, Belgium.; Greil R; Paracelsus Medical University Salzburg, Salzburg Cancer Research Institute-CCCIT and Cancer Cluster Salzburg, Salzburg, Austria.; Matsubara N; Department of Medical Oncology, National Cancer Center Hospital East, Chiba, Japan.; Tan DSW; Division of Medical Oncology, National Cancer Centre Singapore, Singapore.; Wong A; Department of Haematology-Oncology, National University Cancer Institute, Singapore.; Uemura H; Department of Urology and Renal Transplantation, Yokohama City University Medical Center, Yokohama, Japan.; Lemech C; Scientia Clinical Research, University of New South Wales, Randwick, Australia.; Meran J; Department of Internal Medicine, Hematology, and Internal Oncology, Hospital Barmherzige Brueder, Vienna, Austria.; Yu Y; Global Biostatistical Science, Amgen Inc., Thousand Oaks, California.; Minocha M; Clinical Pharmacology M&S, Amgen Inc., Thousand Oaks, California.; McComb M; Clinical Pharmacology M&S, Amgen Inc., Thousand Oaks, California.; Penny HL; Clinical Immunology, Amgen Inc., Thousand Oaks, California.; Gupta V; Clinical Biomarkers, Amgen Inc., Thousand Oaks, California.; Hu X; Clinical Biomarkers, Amgen Inc., Thousand Oaks, California.; Jurida G; Safety TA & Combination Products, Amgen Inc., Thousand Oaks, California.; Kouros-Mehr H; Global Development, Amgen Inc., Thousand Oaks, California.; Janát-Amsbury MM; Early Development, Oncology, Amgen Inc., Thousand Oaks, California.; Eggert T; Early Development, Oncology, Amgen Inc., Thousand Oaks, California.; Tran B; Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Australia.
Publisher: American Association for Cancer Research Country of Publication: United States NLM ID: 9502500 Publication Model: Print Cited Medium: Internet ISSN: 1557-3265 (Electronic) Linking ISSN: 10780432 NLM ISO Abbreviation: Clin Cancer Res Subsets: MEDLINE
Academic Journal
Burris HA; Sarah Cannon Research Institute, Nashville, TN, USA. howard.burris@scri.com.; Berlin J; Division of Hematology/Oncology, Vanderbilt-Ingram Cancer Center, Nashville, TN, USA.; Arkenau T; Drug Development, Ellipses Pharma, London, UK.; Cote GM; Division of Hematology and Oncology, Mass General Cancer Center, Boston, MA, USA.; Lolkema MP; Department of Medical Oncology, Erasmus MC Cancer Institute, Utrecht, Netherlands.; Amgen Inc., Thousand Oaks, CA, USA.; Ferrer-Playan J; Global Clinical Development, Ares Trading SA, an affiliate of Merck KGaA, Eysins, Switzerland.; Kalapur A; Global Patient Safety Oncology, Merck Healthcare KGaA, Darmstadt, Germany.; Bolleddula J; Quantitative Pharmacology, EMD Serono Research & Development Institute, Inc., an affiliate of Merck KGaA, Billerica, MA, USA.; Locatelli G; Clinical Biomarkers, Merck Healthcare KGaA, Darmstadt, Germany.; Goddemeier T; Biostatistics, Merck Healthcare KGaA, Darmstadt, Germany.; Gounaris I; Global Clinical Development, Merck Serono Ltd., an affiliate of Merck KGaA, Feltham, UK.; de Bono J; Division of Clinical Studies, Institute of Cancer Research, London, UK.; Royal Marsden, Hospital, London, UK.
Publisher: Nature Publishing Group on behalf of Cancer Research UK Country of Publication: England NLM ID: 0370635 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1532-1827 (Electronic) Linking ISSN: 00070920 NLM ISO Abbreviation: Br J Cancer Subsets: MEDLINE
Academic Journal
Rijnders M; Department of Medical Oncology, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, The Netherlands.; Nakauma-González JA; Department of Medical Oncology, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, The Netherlands.; Department of Urology, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, The Netherlands.; Cancer Computational Biology Center, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, The Netherlands.; Robbrecht DGJ; Department of Medical Oncology, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, The Netherlands.; Gil-Jimenez A; Department of Molecular Carcinogenesis, The Netherlands Cancer Institute, Amsterdam, The Netherlands.; Oncode Institute, Utrecht, The Netherlands.; Balcioglu HE; Department of Medical Oncology, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, The Netherlands.; Oostvogels AAM; Department of Medical Oncology, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, The Netherlands.; Aarts MJB; Department of Medical Oncology, GROW-School for Oncology and Reproduction, Maastricht University Medical Center, Maastricht, The Netherlands.; Boormans JL; Department of Urology, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, The Netherlands.; Hamberg P; Department of Medical Oncology, Franciscus Gasthuis & Vlietland Hospital, Rotterdam/Schiedam, The Netherlands.; van der Heijden MS; Department of Molecular Carcinogenesis, The Netherlands Cancer Institute, Amsterdam, The Netherlands.; Department of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.; Szabados BE; Barts Cancer Institute, Queen Mary University of London, London, UK.; van Leenders GJLH; Department of Pathology, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, The Netherlands.; Mehra N; Department of Medical Oncology, Radboud University Medical Center, Nijmegen, The Netherlands.; Voortman J; Department of Medical Oncology, Amsterdam UMC, Vrije Universiteit Amsterdam, Cancer Center Amsterdam, Amsterdam, The Netherlands.; Westgeest HM; Department of Internal Medicine, Amphia Hospital Breda, Breda, The Netherlands.; de Wit R; Department of Medical Oncology, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, The Netherlands.; van der Veldt AAM; Department of Medical Oncology, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, The Netherlands.; Department of Radiology & Nuclear Medicine, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, The Netherlands.; Debets R; Department of Medical Oncology, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, The Netherlands. j.debets@erasmusmc.nl.; Lolkema MP; Department of Medical Oncology, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, The Netherlands.; Amgen Inc., Breda, The Netherlands.
Publisher: Nature Pub. Group Country of Publication: England NLM ID: 101528555 Publication Model: Electronic Cited Medium: Internet ISSN: 2041-1723 (Electronic) Linking ISSN: 20411723 NLM ISO Abbreviation: Nat Commun Subsets: MEDLINE
Report
Kroenke MA; Clinical Immunology, Amgen, Thousand Oaks, CA, United States.; Starcevic Manning M; Translational Safety & Bioanalytical Sciences, Amgen, Thousand Oaks, CA, United States.; Zuch de Zafra CL; Translational Safety & Bioanalytical Sciences, Amgen, South San Francisco, CA, United States.; Zhang X; Clinical Pharmacology, Modeling, and Simulation, Amgen, South San Francisco, CA, United States.; Cook KD; Pharmacokinetics and Drug Metabolism, Amgen, South San Francisco, CA, United States.; Archer M; Global Safety, Amgen, Thousand Oaks, CA, United States.; Lolkema MP; Early Development, Amgen, Thousand Oaks, CA, United States.; Wang J; Translational Safety & Bioanalytical Sciences, Amgen, Thousand Oaks, CA, United States.; Hoofring S; Translational Safety & Bioanalytical Sciences, Amgen, Thousand Oaks, CA, United States.; Saini G; Translational Safety & Bioanalytical Sciences, Amgen, Thousand Oaks, CA, United States.; Aeffner F; Translational Safety & Bioanalytical Sciences, Amgen, South San Francisco, CA, United States.; Ahern E; Medical Oncology, Monash Health, Clayton, VIC, Australia.; Cabanas EG; Research Unit, Hospital Universitario Vall d'Hebron, Barcelona, Spain.; Govindan R; Division of Hematology and Oncology, Washington University Medical School, St. Louis, MO, United States.; Hui M; Chris O'Brien Lifehouse, Camperdown, NSW, Australia.; Gupta S; Translational Safety & Bioanalytical Sciences, Amgen, Thousand Oaks, CA, United States.; Mytych DT; Clinical Immunology, Amgen, Thousand Oaks, CA, United States.
Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101560960 Publication Model: eCollection Cited Medium: Internet ISSN: 1664-3224 (Electronic) Linking ISSN: 16643224 NLM ISO Abbreviation: Front Immunol Subsets: MEDLINE
Academic Journal
Pruis MA; Department of Oncology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands.; Krebs MG; Division of Cancer Sciences, Faculty of Biology, Medicine and Health, The University of Manchester and The Christie NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, UK.; Plummer R; Oncology Department, Newcastle University and Newcastle Hospitals NHS Foundation Trust, Newcastle, UK.; De Vos F; Department Medical Oncology, University Medical Center Utrecht, University Utrecht, Utrecht, The Netherlands.; Angevin E; Drug Development Department (DITEP), Gustave Roussy Institute, Villejuif, France.; Prenen H; Department of Medical Oncology, University Hospital Antwerp, Antwerp, Belgium.; Forster MD; Department of Oncology, UCL Cancer Institute/ University College London Hospitals NHS Foundation Trust, London, UK.; Clack G; Octimet Oncology NV, Belgium.; Van der Aa A; Octimet Oncology NV, Belgium.; Tjwa M; Octimet Oncology NV, Belgium.; Jansen E; Octimet Oncology NV, Belgium.; Perera T; Department of Oncology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands.; Octimet Oncology NV, Belgium.; Lolkema MP; Department of Oncology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands.
Publisher: Oxford University Press Country of Publication: England NLM ID: 9607837 Publication Model: Print Cited Medium: Internet ISSN: 1549-490X (Electronic) Linking ISSN: 10837159 NLM ISO Abbreviation: Oncologist Subsets: MEDLINE
검색 결과 제한하기
제한된 항목
[Author] Lolkema MP
발행연도 제한
-
학술DB(Database Provider)
저널명(출판물, Title)
출판사(Publisher)
자료유형(Source Type)
주제어
언어